[BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer].
OBJECTIVE
The aim of this study is to determine the short-term efficacy, toxicity and the rate of life-quality improvement of BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer (NSCLC) by comparation with PT regimen alone.


METHODS
Sixty patients with NSCLC were randomly divided into the treatment group and control group, with 30 each. The treatment group was treated with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1+cisplatin: 20 mg/m2 ivdirp qd d1-5) in combination with BSD2000 deep hyperthermia, and hyperthermia was positioned precisely and maintained for 60 min (2 times a cycle: d1, 4 after the end of chemotherapy within two hours). The control group was treated with chemotherapy alone. Treatment response in both groups were evaluated as well as side-effects after 3 cycles. By observing the results, comparing response rate, toxic side effects and quality of life improvement rate in two groups.


RESULTS
The efficiency and the rate of life-quality improvement in the treatment group were 63.33%, 76.67% respectively, and 36.67%, 40.00% in the control group respectively. There were significant differences between two groups (P < 0.05). The main side-effects were myelosuppression and gastrointestinal reactions, no significant difference between two groups (P > 0.05).


CONCLUSIONS
BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can significantly increase the efficacy, response rate and quality of life improvement and without increasing side-effects compared to chemotherapy alone.
Yang
Mengxiang
M
Department of Medical Oncology, Liaocheng People's Hospital, Liaocheng 252000, China. ymx1405@sina.com
Zhao
Jun
J
Wang
Yanwen
Y
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use; D016896:Treatment Outcome
D017239:Paclitaxel